| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S00432-012-1358-0 |
| P698 | PubMed publication ID | 23224376 |
| P2093 | author name string | T Fehm | |
| D Wallwiener | |||
| C Bachmann | |||
| J Schittenhelm | |||
| A Staebler | |||
| E M Grischke | |||
| P2860 | cites work | Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). | Q43846885 |
| Trastuzumab treatment beyond brain progression in HER2-positive metastatic breast cancer | Q44176007 | ||
| Do we need HER-2/neu testing for all patients with primary breast carcinoma? | Q44688895 | ||
| Immunohistochemical profiles of brain metastases from breast cancer | Q46467683 | ||
| HER-2/neu Status in Breast Cancer Metastases to the Central Nervous System | Q47434711 | ||
| erbB-2 (HER-2) and breast cancer progression. | Q47634701 | ||
| Trastuzumab prolongs overall survival in patients with brain metastases from Her2 positive breast cancer | Q48142933 | ||
| Increased rate of brain metastasis with trastuzumab therapy not associated with impaired survival | Q48253215 | ||
| Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer | Q48371008 | ||
| HER2 in brain metastases: issues of concordance, survival, and treatment. | Q48479849 | ||
| Association of c-erbB-2 protein over-expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer | Q48624908 | ||
| Central nervous system metastasis from breast carcinoma. Autopsy study | Q48704506 | ||
| 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. | Q53243856 | ||
| Defining prognosis for women with breast cancer and CNS metastases by HER2 status | Q80853598 | ||
| Risk factors for brain relapse in patients with metastatic breast cancer | Q80945449 | ||
| Extended survival in women with brain metastases from HER2 overexpressing breast cancer | Q81399965 | ||
| Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. | Q27824766 | ||
| Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group | Q27824835 | ||
| Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer | Q29616112 | ||
| Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review | Q33561966 | ||
| Multifactorial central nervous system recurrence susceptibility in patients with HER2-positive breast cancer: epidemiological and clinical data from a population-based cancer registry study. | Q33878643 | ||
| HER3 and downstream pathways are involved in colonization of brain metastases from breast cancer | Q34173413 | ||
| The prognostic contribution of clinical breast cancer subtype, age, and race among patients with breast cancer brain metastases | Q34696334 | ||
| Estrogen and HER-2 Receptor Discordance Between Primary Breast Cancer and Metastasis | Q35583809 | ||
| Cardiotoxicity and incidence of brain metastases after adjuvant trastuzumab for early breast cancer: the dark side of the moon? A meta-analysis of the randomized trials | Q36885522 | ||
| Survival among women with triple receptor-negative breast cancer and brain metastases | Q37293398 | ||
| Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases? | Q37316222 | ||
| The upgraded role of HER3 and HER4 receptors in breast cancer. | Q37501461 | ||
| Human epidermal growth factor receptor 2-positive breast cancer and central nervous system metastases | Q37601140 | ||
| Changes in estrogen receptor, progesterone receptor and Her-2/neu status with time: discordance rates between primary and metastatic breast cancer. | Q38421601 | ||
| Predominance of the basal type and HER-2/neu type in brain metastasis from breast cancer | Q42513522 | ||
| Hormone receptor and c-ERBB2 status in distant metastatic and locally recurrent breast cancer. Pathologic correlations and clinical significance | Q43162626 | ||
| P433 | issue | 4 | |
| P921 | main subject | immunohistochemistry | Q899285 |
| P304 | page(s) | 551-556 | |
| P577 | publication date | 2012-12-06 | |
| P1433 | published in | Journal of Cancer Research and Clinical Oncology | Q2081599 |
| P1476 | title | CNS metastases of breast cancer show discordant immunohistochemical phenotype compared to primary | |
| P478 | volume | 139 |
| Q91768397 | A novel panel of differentially-expressed microRNAs in breast cancer brain metastasis may predict patient survival |
| Q39456912 | Brain Metastasis: Clinical Implications of Branched Evolution |
| Q46011361 | CNS metastases in breast cancer patients: prognostic implications of tumor subtype. |
| Q37174919 | Changing molecular profile of brain metastases compared with matched breast primary cancers and impact on clinical outcomes |
| Q47870184 | Discrepancies between biomarkers of primary breast cancer and subsequent brain metastases: an international multicenter study. |
| Q42367836 | Genetic Characterization of Brain Metastases in the Era of Targeted Therapy. |
| Q38829087 | Immunotherapy and targeted therapy in brain metastases: emerging options in precision medicine. |
| Q38756841 | Molecular pathology in real time |
| Q89161805 | Profiles of brain metastases: Prioritization of therapeutic targets |
| Q44678963 | Receptor change-clinicopathologic analysis of matched pairs of primary and cerebral metastatic breast cancer |
| Q54379038 | Risk factors and survival outcome in cerebral metastatic breast cancer. |
Search more.